Literature DB >> 1662022

Influence of albumin on itraconazole and ketoconazole antifungal activity: results of a dynamic in vitro study.

M Schäfer-Korting1, H C Korting, F Amann, R Peuser, A Lukacs.   

Abstract

The relevance of intense protein binding to the antifungal activity of azole compounds is still a matter of debate. The influence of albumin on the antimicrobial activity of ketoconazole and itraconazole, which exhibit very strong plasma protein binding (99 and 99.8%), was evaluated in vitro. Candida albicans was exposed to continuously changing azole concentrations corresponding to drug levels in serum following an oral dose of 200 mg. Total as well as free drug levels in serum were simulated. The incubation medium was free of proteins or contained 4% human serum albumin. Itraconazole levels reflecting free drug concentrations in humans did not reduce the growth rate of C. albicans, as compared with controls (difference in the log CFU per milliliter at 12 h, 0.03 +/- 0.09), whereas total drug levels were as active in the presence of 4% albumin (mean difference, -0.61) as in its absence (-0.75). The same was true for ketoconazole, except that free drug levels were also active (-1.21 versus -1.39 for total drug levels). This result was due to the higher ketoconazole levels in humans. Thus, in terms of routine susceptibility testing, in vitro total drug levels can be considered relevant.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1662022      PMCID: PMC245325          DOI: 10.1128/AAC.35.10.2053

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Can the clinical efficacy of different antibiotic dosage regimens in gonorrhoea be predicted from the gonocidal effect of the corresponding plasma level profiles simulated in vitro?

Authors:  H C Korting; M Ollert; A Lukacs; M Schäfer-Korting
Journal:  Acta Derm Venereol       Date:  1987       Impact factor: 4.437

2.  [Antimicrobial effects of in vitro-simulated ketoconazole-cantharidin blister fluid levels on candida albicans].

Authors:  H C Korting; U Schlaf-Maier; M Schäfer-Korting
Journal:  Mykosen       Date:  1986-07

Review 3.  The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy.

Authors:  R Wise
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

Review 4.  Problems in therapeutic drug monitoring: free drug level monitoring.

Authors:  J Barre; F Didey; F Delion; J P Tillement
Journal:  Ther Drug Monit       Date:  1988       Impact factor: 3.681

5.  Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration.

Authors:  M Schäfer-Korting; H C Korting; A Lukacs; J Heykants; H Behrendt
Journal:  J Am Acad Dermatol       Date:  1990-02       Impact factor: 11.527

6.  In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy.

Authors:  K A McIntyre; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

7.  An amino acid liquid synthetic medium for the development of mycelial and yeast forms of Candida Albicans.

Authors:  K L Lee; H R Buckley; C C Campbell
Journal:  Sabouraudia       Date:  1975-07

8.  Pharmacokinetics and pharmacodynamics of total and unbound cefoxitin and cefotetan in healthy volunteers.

Authors:  P L Carver; C H Nightingale; R Quintiliani
Journal:  J Antimicrob Chemother       Date:  1989-01       Impact factor: 5.790

9.  Skin blister fluid levels of ketoconazole during repetitive administration in healthy man.

Authors:  H C Korting; A Lukacs; M Schäfer-Korting; J Heykants; H Behrendt
Journal:  Mycoses       Date:  1989-01       Impact factor: 4.377

10.  Evaluation of YeastIdent and Uni-Yeast-Tek yeast identification systems.

Authors:  I F Salkin; G A Land; N J Hurd; P R Goldson; M R McGinnis
Journal:  J Clin Microbiol       Date:  1987-04       Impact factor: 5.948

View more
  12 in total

Review 1.  In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis.

Authors:  David Andes
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  Effects of serum on in vitro susceptibility testing of echinocandins.

Authors:  Zekaver Odabasi; Victor Paetznick; John H Rex; Luis Ostrosky-Zeichner
Journal:  Antimicrob Agents Chemother       Date:  2007-09-04       Impact factor: 5.191

3.  Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.

Authors:  Mikko Niemi; Janne T Backman; Laura Juntti-Patinen; Mikko Neuvonen; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

4.  Influence of human serum on antifungal pharmacodynamics with Candida albicans.

Authors:  G G Zhanel; D G Saunders; D J Hoban; J A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

5.  Cholesterol import by Aspergillus fumigatus and its influence on antifungal potency of sterol biosynthesis inhibitors.

Authors:  Quanbo Xiong; Saad A Hassan; William K Wilson; Xiang Y Han; Gregory S May; Jeffrey J Tarrand; Seiichi P T Matsuda
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

6.  Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Marina McIver; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

7.  Influence of serum protein binding on the in vitro activity of anti-fungal agents.

Authors:  M Schäfer-Korting; H C Korting; W Rittler; W Obermüller
Journal:  Infection       Date:  1995 Sep-Oct       Impact factor: 3.553

Review 8.  Pharmacokinetic optimisation of oral antifungal therapy.

Authors:  M Schäfer-Korting
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

9.  In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model.

Authors:  D Andes; K Marchillo; T Stamstad; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

10.  Effect of itraconazole on the pharmacokinetics of diclofenac in beagle dogs.

Authors:  Fahad I Al-Jenoobi
Journal:  Sci Pharm       Date:  2010-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.